JAK2 is a promising target for treating myeloproliferative neoplasms (MPNs).
However, existing JAK2 inhibitors cannot fully cure these diseases and may induce resistance with prolonged use.
Here, we report the design, synthesis, and biological evaluation of a series of highly potent JAK2 degraders based on our previously developed inhibitor WWQ-131.
The optimal compound
